<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03167775</url>
  </required_header>
  <id_info>
    <org_study_id>81YY-ZLLL-16-19</org_study_id>
    <nct_id>NCT03167775</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer</brief_title>
  <official_title>Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiJing Yijiayi Medicine Techonoloy Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dalian Holley Kingkong Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BeiJing Yijiayi Medicine Techonoloy Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best&#xD;
      Supportive Treatment in the Treatment of Advanced Primary Liver Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with advanced primary liver cancer will be enrolled in the trial , then the patients&#xD;
      will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the&#xD;
      best supportive treatment .The purpose of the study is to evaluate the effect and safety of&#xD;
      the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive&#xD;
      treatment in the treatment of advanced primary liver cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 28, 2016</start_date>
  <completion_date type="Anticipated">November 27, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 27, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DCR and/or 6-months survival rate</measure>
    <time_frame>6 months</time_frame>
    <description>Disease control rate.The proportion of patients who had a best response rating of complete response, partial response, or stable disease/</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>1year</time_frame>
    <description>Objective response rate.The proportion of patients who had a best response rating of complete response and partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival.The time of patients from randomization to death caused by the progression of the tumor or any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 year</time_frame>
    <description>Overrall survival.The time of patient from randomization to death caused by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ</measure>
    <time_frame>3 year</time_frame>
    <description>Quality of Life Questionnaire Core 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of incidence of adverse events</measure>
    <time_frame>3 year</time_frame>
    <description>NCI CTC AE 4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Primary Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Elemene + the best supportive treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elemene Injection/Elemene Oral Emulusion</intervention_name>
    <arm_group_label>Elemene + the best supportive treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-75 years old，No limit on gender&#xD;
&#xD;
          -  Patients who are confirmed Locally advanced or metastatic primary liver cancerin&#xD;
             accordance with the clinical diagnostic criteria , or by pathological histology or&#xD;
             cytology examination, Patients who are unable to accept surgery,radiofrequency&#xD;
             ablation、TACE and local therapy ，orLocal treatment progress failed&#xD;
&#xD;
          -  have systematic treatment before( including systematic chemotherapy and/or molecular&#xD;
             targeted therapy) , but the treatment was unsuccessed and the tumor progress&#xD;
&#xD;
          -  According to RECIST V1.1，1at least has one measurable lesions&#xD;
&#xD;
          -  ECOG Score ≤2&#xD;
&#xD;
          -  Patients who have primary liver cancer with Child - Pugh liver function grade rating A&#xD;
             or better B(score&lt;=7)&#xD;
&#xD;
          -  Laboratory inspection basically meets the following requirements： Blood test：a.&#xD;
             Hb&gt;=90g/L(without blood transfusion within 14 days), b. ANC&gt;=1.5×10^9/L, c.&#xD;
             PLT&gt;=60×10^9/L. Biochemical test：a. ALB&gt;=29g/L(without blood transfusion within 14&#xD;
             days), b. ALT and AST &lt;=5ULN, c. TBIL&lt;=2ULN, d. Cr&lt;=1.5ULN. Blood Coagulation&#xD;
             function:PT&lt;=ULN+6seconds.&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Subjects join the study voluntarily, sign a consent form, have good compliance, and&#xD;
             comply with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients have other anti-cancer treatment ， including α-IFN，Arsenious Acid Injection&#xD;
             and other Traditional Chinese Medicine Patent Prescription for treating cancer&#xD;
&#xD;
          -  In the past or at the same time,patients were diagnosed with other malignant tumor&#xD;
             which have not been cured. As for skin basal cell carcinoma and cervical carcinoma in&#xD;
             situ,they can be excepted&#xD;
&#xD;
          -  Patients with severe acute infection and cann't be controled , Chronic suppurative&#xD;
             infection , body temperature&gt;=39℃ ， Pleural effusion（medium and large） combined with&#xD;
             infection&#xD;
&#xD;
          -  Women who is pregnant or during breast feeding and not willing to contraception during&#xD;
             the test&#xD;
&#xD;
          -  Coagulation dysfunction(PT&gt;16 seconds ， APTT&gt;43 seconds , TT&gt;21 seconds , Fib&lt;2g/L) ,&#xD;
             With bleeding tendency or the presence of vital organ thrombosis (lung, brain) is&#xD;
             receiving thrombolytic or anticoagulant therapy&#xD;
&#xD;
          -  With a mental illness, or has a history of drugs abuse&#xD;
&#xD;
          -  Patients accepted any experimental drugs in the past 4 weeks&#xD;
&#xD;
          -  Other reasons the researchers think not suitable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shukui Qin</last_name>
    <phone>025-80864541</phone>
    <email>qinsk@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Medical University Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huaimin Liu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

